论文部分内容阅读
目的观察肝胆舒康胶囊治疗终末期乙型病毒性肝炎的临床疗效。方法将106例终末期乙型肝炎患者随机分为对照组(51例)和治疗组(55例);对照组采用口服阿德福韦酯片治疗,治疗组口服阿德福韦酯片和肝胆舒康胶囊,疗程均为48周。结果治疗后,两组血清HA、LN、PCⅢ均较治疗前明显降低(P<0.01),且治疗组低于对照组(P<0.05);治疗组门静脉内径和脾厚度缩小(P<0.05),且较对照组小(P<0.05)。结论阿德福韦酯片联合肝胆舒康胶囊治疗终末期乙型病毒性肝炎疗效确切。
Objective To observe the clinical efficacy of HeGan ShuKang capsule in the treatment of end-stage hepatitis B virus. Methods 106 patients with end-stage hepatitis B were randomly divided into control group (n = 51) and treatment group (n = 55). The control group was treated with oral adefovir dipivoxil tablets. The treatment group received oral adefovir dipivoxil tablets and hepatobiliary Shukang capsules, treatment are 48 weeks. Results After treatment, the levels of serum HA, LN and PCⅢ in both groups were significantly lower than those before treatment (P <0.01), and were lower in the treatment group than those in the control group (P <0.05) , And smaller than the control group (P <0.05). Conclusion adefovir dipivoxil tablets combined with Hepatobiliary Shukang capsule treatment of end-stage hepatitis B virus is effective.